3Z Pharmaceuticals (private company)

See something wrong or missing? Let us know
Offices:Reykjavik
Business model:B2B

3Z was founded in 2008 by Karl Karlsson, Reykjavik University, and Haraldur Thorsteinsson. It originates from RU neurolab, a Reykjavik University based neuroscience laboratory, in which a zebrafish model of sleep has been in development since 2006.

Karl Karlsson is a professor at the School of Science and Engineering at Reykjavik University. He obtained a Phd in Behavioral Neuroscience from Iowa University in 2005. In 2006 Karlsson started RU Neurolab, a laboratory focused on the neurobiology of sleep and wake. Haraldur Thorsteinsson joined RU Neurolab in 2008. He received an MSc. in Neuropsychology from the University of Maastricht in 2008.

At RU Neurolab a zebrafish model for studying sleep and wake physiology has been developed and is currently employed in high throughput screening. Other core methods employed in the lab include automated behavioral analysis, basic genetics, histology and in vivo/in vitro electrophysiology.

Investors: we tracked 4 investors

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 2.4M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to 3Z Pharmaceuticals

Name Criteria
France Pharmedigroup
60%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 1
  • Total raised in a similar range: 1M - 5M USD
France PEP-Therapy
60%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 2
  • Total raised in a similar range: 1M - 5M USD
Sweden Pila Pharma
57%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one other investor: found 1
  • Total raised in a similar range: 1M - 5M USD
France Vaxxel
57%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one other investor: found 1
  • Total raised in a similar range: 1M - 5M USD
Norway Avexxin
55%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 1
United Kingdom Beckley Psytech
55%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 2
Sweden Cinclus Pharma
55%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 2
Denmark Octarine Bio
55%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • Total raised in a similar range: 1M - 5M USD
France Synapse Medicine
55%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 2
Sweden Trialbee
55%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • At least one vc investor: found 1
  • At least one other investor: found 1
Top